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Electrospray ionization mass spectrometry (ESI-MS) was assessed as a tool for the 
analysis of different glycosylated and iron forms of transferrin (tf).  Carbohydrate 
deficient transferrin (CDT) is clinically relevant in the diagnosis of congenital disorders 
of glycosylation (CDG) and in monitoring compliance in rehabilitation programs for 
alcoholism.  The iron load of transferrin is an indicator of iron deficiency (or 
sufficiency).  The concentration ranges (5 – 15 µM)  over which the ESI-MS response 
for tf was λινεαρ  were determined in 0.1 M NH4HCO3, pH 8.2, and in 1% formic acid.   
In order to develop a method for analysis by ESI-MS, optimal conditions were 
determined for obtaining CDT from commercial apo-tf by treatment with neuraminidase 
or PNGase.  The resulting CDT forms were separated by HPLC and analysed by ESI-
MS.  The abundant human serum albumin was removed from plasma by loading 25-75 
µl of plasma onto a Micro Bio-Spin column containing Cibacron Blue-agarose.  A high 
quality ESI mass spectrum of tf was obtained from the eluent.  Using ESI-MS it was 
possible to distinguish between commercial holo-tf (Fe2-tf) and apo-tf (Fe0-tf).  The 
rapid analysis of transferrin from plasma by ESI-MS lays the foundation for 
development of a clinical method for analysing CDT and possibly for determining the 
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